Allspring Growth Fund Q4 2025 Fund Performers And Detractors

Carpenter Technology Corp. multiple long-term contracts were repriced favorably as airlines keep aging fleets in service longer driving higher maintenance needs. Natera, Inc. doubled the number of oncology sales representatives to drive awareness and volumes in 2026. Natera, Inc. doubled the number of oncology sales representatives to drive awareness and volumes in 2026.

Seeking Alpha • Feb 13, 2026

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company's non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications. Preeclampsia affects approximately 5-8% of pregnancies and remains a leading cause of maternal and neonatal morbidity.1 While clinical guidelines re.

Business Wire • Feb 6, 2026

Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test

NTRA submits FDA PMA for Signatera CDx, aiming to guide bladder cancer treatment with MRD testing after positive phase 3 trial results.

Zacks Investment Research • Feb 3, 2026

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.

Seeking Alpha • Feb 3, 2026

Natera Submits Signatera™ CDx PMA to FDA

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®). This submission is supported by data from the randomized, double-blind, phase 3 IMvi.

Business Wire • Feb 2, 2026

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.

Seeking Alpha • Jan 29, 2026

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera's Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients. Positive results would support a fundamental shift in the standard of care for heart transplant recipients away from invasive tissue sampling.

Business Wire • Jan 28, 2026

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center (OSU-WMC), was initiated to explore whether donor-derived cell-free DNA (dd-cfDNA) surveillance, and specifically Prospera-guided monitoring, could reduce the number of invasive biopsies for patients foll.

Business Wire • Jan 26, 2026

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Nebius Group, Wix.com Ltd., and Rezolute, Inc. were among the top detractors from performance.

Seeking Alpha • Jan 26, 2026

Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractors from performance. During the quarter, Robinhood shares detracted from performance, primarily due to a sharp decline in cryptocurrency markets.

Seeking Alpha • Jan 22, 2026